Original Source(s)
Related Content
FDA Expands Bladder Cancer Regimen
KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.
July 10, 2026
-
2 min
New CDC Report Tracks US Mortality Trends
The annual provisional report summarizes changes in mortality rates, demographic patterns, and leading causes of death during 2025.
July 13, 2026
-
3 min
Low IMA Ligation Did Not Significantly Reduce Leaks
A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.
July 15, 2026
-
5 min
